A Phase 1 interventional study of GenSci148 Injection in Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Retinal Vein Occlusion with a site in China — 8 open to participants now, 12 under way, 1 of them phase 3. Retinal Vein Occlusion · China.
Among the 36 studies in Retinal Vein Occlusion with a site in China, this one is the 20th largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 1, reaches primary completion later than 10 of the 11 other live ones, and was the 36th registered.
289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.
Browse Retinal Vein Occlusion studies →8 of the 36 studies in Retinal Vein Occlusion with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–80
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 50+
Renmin Hospital of Wuhan University · Sites in China
Ages 18+
Renmin Hospital of Wuhan University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 11 · Phase 4 3
First in 2011; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 51 across 208 interventional studies indexed under Retinal Vein Occlusion.
Median enrollment 135 across the 26 interventional studies, 874 across the 10 observational. Of the 19 that completed or were terminated, 7 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 36 have an industry lead sponsor. The 10 most frequent:
Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.
Changchun GeneScience Pharmaceutical Co., Ltd. has 1 study filed under Retinal Vein Occlusion — fewer than ten, so there is no comparison to draw.
2 of the studies in Retinal Vein Occlusion with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07201415Zhongnan HospitalMinimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma | 2026-12-31 |
| NCT07133438First Affiliated Hospital of Chongqing Medical UniversityMecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Retinal Vein Occlusion with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I, multicenter, open-label, dose-escalation study conducted in two parts to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GenSci148 administered via intravitreal (IVT) injection in participants with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Part 1 evaluates single ascending doses in nAMD participants. Part 2 evaluates multiple doses in nAMD, DME, and RVO participants. The study also assesses immunogenicity and explores preliminary efficacy.
This is a Phase I, multicenter, open-label, dose-escalation study conducted in 2 parts to evaluate the safety, tolerability, PK and PD profiles, and immunogenicity, as well as the preliminary efficacy of intravitreal injection of GenSci148 in participants with nAMD, DME and RVO.
Part 1 (Single Ascending Dose, SAD): Conducted in participants with nAMD. Four dose levels (1 mg/eye, 3 mg/eye, 7 mg/eye, and 10 mg/eye) are planned, administered via a single IVT injection. Dose escalation is determined by the Safety Review Committee (SRC) based on safety, tolerability, PK, PD, and other available data.
Part 2 (Multiple Ascending Dose, MAD): Conducted in participants with nAMD, DME, and RVO. Three dose levels (low, medium, and high) are planned. Participants will receive multiple IVT injections according to the study schedule. Disease activity assessment will be performed during follow-up, and participants meeting retreatment criteria may receive additional doses of GenSci148.
Safety assessments include adverse events, physical examinations, laboratory tests, vital signs, ECG, and ophthalmic examinations (BCVA, IOP, slit-lamp examination, , etc.). PK/PD and immunogenicity samples are collected at predefined time points.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive intravitreal injections of GenSci148 at escalating dose levels. Part 1: single ascending dose (1 mg, 3 mg, 7 mg, 10 mg per eye). Part 2: multiple ascending doses in nAMD, DME, and RVO participants.
Drug: GenSci148 Injection
GenSci148 is a fusion protein that simultaneously targets VEGF-A, VEGF-C, VEGF-D, and Ang-2.
Incidence and severity of treatment-emergent adverse events (TEAEs)
TEAEs include ocular and systemic adverse events, graded by severity and relationship to study drug. Safety assessments include physical examination, vital signs, laboratory tests, ECG, and ophthalmic examinations.
Time frame: 43 days(Part 1) and 40 weeks (Part 2)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Jun 2028, 21 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Changchun GeneScience Pharmaceutical Co., Ltd. →